Search Results

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor Lunch Break: The CNSP Opportunity event on Tuesday, April 23, 2024 at 12:00 PM ET.

CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM in London, England.

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.

CNS Pharmaceuticals, Inc. today reported its financial results for the first quarter 2024 ended March 31, 2024.

CNS Pharmaceuticals, Inc. today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024.

CNS Pharmaceuticals, Inc. announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 366,000 shares of common stock in a registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement at a combined purchase price of $3.75 per share.

CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April.